2025 Q3 -tulosraportti
Vain PDF
70 päivää sitten
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
15 157
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 860 | - | - | ||
| 297 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 100 | - | - |
Ylin
0,32VWAP
Alin
0,3VaihtoMäärä
0,2 640 353
VWAP
Ylin
0,32Alin
0,3VaihtoMäärä
0,2 640 353
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19 t sittenI'm taking a chance on buying BTA under 30 öre! I believe that it's better than subscribing. However, I have sold my TRs so that someone else can subscribe and cushion the fall. I did the same with Medivir and that tactic worked well there. I note that an enormous number of TRs are being sold now. All of them will probably subscribe. I assume that these are people who want to buy a lot without affecting the price.
·18 t sitten · MuokattuNo, if people do as you do, the rights issue will precisely not be a success! You are probably quite right about the share price right after the rights issue, as I also write. But if one is interested in the companies one invests in surviving long-term, one must participate in the rights issues. One can do that without taking money out of one's pocket if one uses the method I describe. If one doesn't want to help secure biotech development, but just bet on earning an extra penny or two, one can try to do as you do. In that case, I would, however, bet completely differently with a greater chance of profit - e.g. Cantargia or Prostatype - or more safely with Linc, which is cheap currently. If you remember the last rights issue in Karolinska and used the same technique then, you know that your technique can go very wrong. But let's hope that it doesn't repeat itself. The technique has also not been good in Immunovia et al. So I think one should participate in the rights issue to support the company's development - and then one can always buy more afterwards if BTAs become too cheap and tempt further.- ·19 t sitten22-1-26 Incredible offer: Get the shares completely free upon issue. The real NAV discount is 99 %. Updated valuation of Net Asset Value in Karolinska Development The official NAV discount right now before the issue at a price of 0,301 SEK is 92,4 % (ibindex.se). After a fully subscribed issue, it will – if one checks ibindex at that time – fall to approx. 77 % at an expected price after issue of 0,30 SEK. This is not how I calculate the discount, as I instead calculate the real NAV discount, as explained below. And it ends up at approx. 99 % (Briefly, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they have bought at a large discount compared to us other shareholders.) But then the real NAV discount in that period will be over 100 %. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs. I calculate the real NAV discount solely in relation to the unlisted shares, as I first fully offset the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offset any debt.) Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares for free – or almost. More precisely, the real NAV discount under these assumptions becomes 99 %. After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this stock, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's Net Asset Value would still be intact in relation to the price. I choose, as I usually do with this type of issues, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders.
·16.1.31 öre now and the sentiment is around zero. Will it be fully subscribed? I am certainly not subscribing! I am so INCREDIBLY tired of these hope companies that really don't belong on the stock market!·19 t sittenNow that the share is valued at approximately the same as the subscription price, one should not subscribe if one does not believe in the company, but one should sell one's TR to cushion the fall on the shares one still holds if one has not already sold them.- ·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.·16.1.Is there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sittenI'm taking a chance on buying BTA under 30 öre! I believe that it's better than subscribing. However, I have sold my TRs so that someone else can subscribe and cushion the fall. I did the same with Medivir and that tactic worked well there. I note that an enormous number of TRs are being sold now. All of them will probably subscribe. I assume that these are people who want to buy a lot without affecting the price.·18 t sitten · MuokattuNo, if people do as you do, the rights issue will precisely not be a success! You are probably quite right about the share price right after the rights issue, as I also write. But if one is interested in the companies one invests in surviving long-term, one must participate in the rights issues. One can do that without taking money out of one's pocket if one uses the method I describe. If one doesn't want to help secure biotech development, but just bet on earning an extra penny or two, one can try to do as you do. In that case, I would, however, bet completely differently with a greater chance of profit - e.g. Cantargia or Prostatype - or more safely with Linc, which is cheap currently. If you remember the last rights issue in Karolinska and used the same technique then, you know that your technique can go very wrong. But let's hope that it doesn't repeat itself. The technique has also not been good in Immunovia et al. So I think one should participate in the rights issue to support the company's development - and then one can always buy more afterwards if BTAs become too cheap and tempt further.
- ·19 t sitten22-1-26 Incredible offer: Get the shares completely free upon issue. The real NAV discount is 99 %. Updated valuation of Net Asset Value in Karolinska Development The official NAV discount right now before the issue at a price of 0,301 SEK is 92,4 % (ibindex.se). After a fully subscribed issue, it will – if one checks ibindex at that time – fall to approx. 77 % at an expected price after issue of 0,30 SEK. This is not how I calculate the discount, as I instead calculate the real NAV discount, as explained below. And it ends up at approx. 99 % (Briefly, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they have bought at a large discount compared to us other shareholders.) But then the real NAV discount in that period will be over 100 %. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs. I calculate the real NAV discount solely in relation to the unlisted shares, as I first fully offset the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offset any debt.) Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares for free – or almost. More precisely, the real NAV discount under these assumptions becomes 99 %. After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this stock, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's Net Asset Value would still be intact in relation to the price. I choose, as I usually do with this type of issues, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders.
- ·16.1.31 öre now and the sentiment is around zero. Will it be fully subscribed? I am certainly not subscribing! I am so INCREDIBLY tired of these hope companies that really don't belong on the stock market!·19 t sittenNow that the share is valued at approximately the same as the subscription price, one should not subscribe if one does not believe in the company, but one should sell one's TR to cushion the fall on the shares one still holds if one has not already sold them.
- ·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.·16.1.Is there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
15 157
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 860 | - | - | ||
| 297 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 100 | - | - |
Ylin
0,32VWAP
Alin
0,3VaihtoMäärä
0,2 640 353
VWAP
Ylin
0,32Alin
0,3VaihtoMäärä
0,2 640 353
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
70 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 13.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 14.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 30.4.2025 | |
| 2024 Q4 -tulosraportti | 14.2.2025 | |
| 2024 Q3 -tulosraportti | 15.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sittenI'm taking a chance on buying BTA under 30 öre! I believe that it's better than subscribing. However, I have sold my TRs so that someone else can subscribe and cushion the fall. I did the same with Medivir and that tactic worked well there. I note that an enormous number of TRs are being sold now. All of them will probably subscribe. I assume that these are people who want to buy a lot without affecting the price.·18 t sitten · MuokattuNo, if people do as you do, the rights issue will precisely not be a success! You are probably quite right about the share price right after the rights issue, as I also write. But if one is interested in the companies one invests in surviving long-term, one must participate in the rights issues. One can do that without taking money out of one's pocket if one uses the method I describe. If one doesn't want to help secure biotech development, but just bet on earning an extra penny or two, one can try to do as you do. In that case, I would, however, bet completely differently with a greater chance of profit - e.g. Cantargia or Prostatype - or more safely with Linc, which is cheap currently. If you remember the last rights issue in Karolinska and used the same technique then, you know that your technique can go very wrong. But let's hope that it doesn't repeat itself. The technique has also not been good in Immunovia et al. So I think one should participate in the rights issue to support the company's development - and then one can always buy more afterwards if BTAs become too cheap and tempt further.
- ·19 t sitten22-1-26 Incredible offer: Get the shares completely free upon issue. The real NAV discount is 99 %. Updated valuation of Net Asset Value in Karolinska Development The official NAV discount right now before the issue at a price of 0,301 SEK is 92,4 % (ibindex.se). After a fully subscribed issue, it will – if one checks ibindex at that time – fall to approx. 77 % at an expected price after issue of 0,30 SEK. This is not how I calculate the discount, as I instead calculate the real NAV discount, as explained below. And it ends up at approx. 99 % (Briefly, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they have bought at a large discount compared to us other shareholders.) But then the real NAV discount in that period will be over 100 %. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs. I calculate the real NAV discount solely in relation to the unlisted shares, as I first fully offset the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offset any debt.) Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares for free – or almost. More precisely, the real NAV discount under these assumptions becomes 99 %. After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this stock, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's Net Asset Value would still be intact in relation to the price. I choose, as I usually do with this type of issues, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders.
- ·16.1.31 öre now and the sentiment is around zero. Will it be fully subscribed? I am certainly not subscribing! I am so INCREDIBLY tired of these hope companies that really don't belong on the stock market!·19 t sittenNow that the share is valued at approximately the same as the subscription price, one should not subscribe if one does not believe in the company, but one should sell one's TR to cushion the fall on the shares one still holds if one has not already sold them.
- ·13.1.I choose, as I usually do with this type of issues, to sell all shares, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to underwriters with further discount and dilution of other shareholders. And since the existing share is still more expensive than the new shares, I also get a few more shares for the same price. So, even with a loss, it's a pure win-win that way, if one wants to stay in the share. The official NAV discount at a price of 0,335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0,30 SEK. (Temporarily, the price can of course become lower right after the issue, as is unfortunately often seen when the underwriters sell off the new shares they bought at a large discount compared to us other shareholders.) However, I am more interested in what I call the real NAV discount. I assume that the share price is 0,30 SEK, that the issue is fully subscribed and adds 203 mio. SEK minus 17. mio., SEK in costs. Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %. I calculate the real NAV discount exclusively in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsetting any debt.) After that, it is of course necessary to look at what unlisted shares are in the company's portfolio. Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know this, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further. But now that the entire pool of unlisted shares is free, much uncertainty can be priced in. Secondly, one must consider the security in relation to how much individual shares fill in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the background for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for it, if Umecrine unexpectedly were to be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.·16.1.Is there ANY company interested, I wonder? Which new major owner in this that is constantly sinking and coming with dilutions? Know too little about bio, but there are quite a few on the small-cap lists and they haven't exactly thrilled the market. Feels safer with GOLD and SILVER these days!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
15 157
Myynti
Määrä
50 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 860 | - | - | ||
| 297 | - | - | ||
| 5 000 | - | - | ||
| 10 000 | - | - | ||
| 100 | - | - |
Ylin
0,32VWAP
Alin
0,3VaihtoMäärä
0,2 640 353
VWAP
Ylin
0,32Alin
0,3VaihtoMäärä
0,2 640 353
Välittäjätilasto
Dataa ei löytynyt